Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $669.05 million. The enterprise value is $640.74 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 90.66 million shares outstanding. The number of shares has increased by 44.36% in one year.
| Current Share Class | 90.66M |
| Shares Outstanding | 90.66M |
| Shares Change (YoY) | +44.36% |
| Shares Change (QoQ) | +18.64% |
| Owned by Insiders (%) | 7.02% |
| Owned by Institutions (%) | 2.91% |
| Float | 20.29M |
Valuation Ratios
The trailing PE ratio is 92.27.
| PE Ratio | 92.27 |
| Forward PE | n/a |
| PS Ratio | 6.30 |
| Forward PS | 6.34 |
| PB Ratio | 9.49 |
| P/TBV Ratio | 10.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 88.37 |
| EV / Sales | 6.37 |
| EV / EBITDA | 52.78 |
| EV / EBIT | 61.43 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.60 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 12.12% and return on invested capital (ROIC) is 6.69%.
| Return on Equity (ROE) | 12.12% |
| Return on Assets (ROA) | 5.18% |
| Return on Invested Capital (ROIC) | 6.69% |
| Return on Capital Employed (ROCE) | 9.41% |
| Revenue Per Employee | $173,822 |
| Profits Per Employee | $12,523 |
| Employee Count | 579 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.59 |
Taxes
In the past 12 months, GYRE has paid $3.68 million in taxes.
| Income Tax | 3.68M |
| Effective Tax Rate | 23.91% |
Stock Price Statistics
The stock price has decreased by -51.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -51.57% |
| 50-Day Moving Average | 8.48 |
| 200-Day Moving Average | 10.55 |
| Relative Strength Index (RSI) | 44.93 |
| Average Volume (20 Days) | 153,744 |
Short Selling Information
The latest short interest is 1.80 million, so 1.99% of the outstanding shares have been sold short.
| Short Interest | 1.80M |
| Short Previous Month | 1.41M |
| Short % of Shares Out | 1.99% |
| Short % of Float | 8.89% |
| Short Ratio (days to cover) | 7.08 |
Income Statement
In the last 12 months, GYRE had revenue of $100.64 million and earned $7.25 million in profits. Earnings per share was $0.02.
| Revenue | 100.64M |
| Gross Profit | 96.84M |
| Operating Income | 10.43M |
| Pretax Income | -74.61M |
| Net Income | 7.25M |
| EBITDA | 12.14M |
| EBIT | 10.43M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $29.89 million in cash and $1.59 million in debt, giving a net cash position of $28.31 million or $0.31 per share.
| Cash & Cash Equivalents | 29.89M |
| Total Debt | 1.59M |
| Net Cash | 28.31M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 104.30M |
| Book Value Per Share | 0.78 |
| Working Capital | 49.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.65 million and capital expenditures -$2.21 million, giving a free cash flow of -$8.86 million.
| Operating Cash Flow | -6.65M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -8.86M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is 96.23%, with operating and profit margins of 10.36% and 7.20%.
| Gross Margin | 96.23% |
| Operating Margin | 10.36% |
| Pretax Margin | 15.27% |
| Profit Margin | 7.20% |
| EBITDA Margin | 12.06% |
| EBIT Margin | 10.36% |
| FCF Margin | n/a |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.36% |
| Shareholder Yield | -44.36% |
| Earnings Yield | 1.08% |
| FCF Yield | -1.32% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GYRE has an Altman Z-Score of 26.76 and a Piotroski F-Score of 4.
| Altman Z-Score | 26.76 |
| Piotroski F-Score | 4 |
